The Delhi High Court has quashed several demand notices of the National Pharmaceutical Pricing Authority (NPPA) by which Bharat Serums and Vaccines and Bard Healthcare India were held guilty of overcharging on drugs and medical devices
IHW Council along with Bharat Serums and Vaccines (BSV) organised the second edition of the National Snakebite Summit to discuss about the gaps in snake bite management in India and to suggest remedial reforms.
Private equity firm Advent-backed Bharat Serums and Vaccines (BSV) on Tuesday said it has acquired Tidilan (isoxsuprine hydrochloride), a leading brand in women’s health from Bengaluru-based Jagdale Industries.
Covid-19 has already claimed about a million lives globally and the toll is rising. As the development of vaccines or any drug will take time, research on Sars-CoV-2 neutralising antibodies is gaining ground to fill an unmet demand in therapy.
India-based Bharat Serums and Vaccines (BSVL) has secured regulatory approval to assess sepsis drug, Ulinastatin, in Phase III clinical trial to treat Covid-19.
India-based Bharat Serums and Vaccines (BSVL) has secured regulatory approval to assess sepsis drug, Ulinastatin, in Phase III clinical trial to treat Covid-19.
Private equity group Advent International is buying a controlling stake in Mumbai-based biopharma company Bharat Serums and Vaccines (BSV), valuing the company for $500 million (Rs 3500 cr). A formal announcement is expected later today.
Private equity group Advent International has emerged as the sole contender for acquiring Mumbai-based biopharma company Bharat Serums and Vaccines (BSV) with a bid worth Rs 3,600 crore ($520 million) after rival contenders backed out of the two-year-long sale process, industry officials close to the development told ET.
Bharat Serums and Vaccines (BSV), the Mumbai-based biopharmaceutical firm known for its niche and differentiated products, is back in the news again.
Drug pricing watchdog National Pharmaceutical Pricing Authority (NPPA) has slashed prices of more than 40 medicines, including those to treat cancer, HIV and blood clots, in its latest price notification. This round of price caps has resulted in a reduction of Rs 20 crore, according to the body.